Masahide Enomoto, Kosuke Kaji, Norihisa Nishimura, Yuki Fujimoto, Koji Murata, Soichi Takeda, Yuki Tsuji, Yukihisa Fujinaga, Hiroaki Takaya, Hideto Kawaratani, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji
BACKGROUND: Although gut-derived lipopolysaccharide (LPS) affects the progression of non-alcoholic steatohepatitis (NASH) pathogenesis, few studies have focused on this relationship to develop treatments for NASH. AIMS: To explore the effects of combination with rifaximin and lubiprostone on NASH liver fibrosis through the modulation of gut barrier function. METHODS: To induce steatohepatitis, F344 rats were fed a choline-deficient l-amino acid-defined (CDAA) diet for 12 weeks and received oral administration of rifaximin and/or lubiprostone...
May 2, 2022: Digestive and Liver Disease